Dr. Freidoon Ghazi, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 49
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,603
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
OH license 35-050071 -
Specialist
OH license 35-050071
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bethesda North Cincinnati, OH
- Good Samaritan Hospital Cincinnati, OH
- Mccullough-Hyde Memorial Hospital Oxford, OH
- Highland District Hospital Hillsboro, OH
Medical groups
- Trihealth H LLC (850 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,603
- Services billed
- 3,754
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 772 | 656 |
| Established patient office or other outpatient visit, 30-39 minutes | 623 | 362 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 376 | 287 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 244 | 241 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 180 | 89 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 175 | 108 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 149 | 72 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 104 | 101 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 88 | 18 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 88 | 18 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Metoprolol Succinate Other prescribers in Cincinnati, OH | 222 |
| Eliquis (apixaban) Other prescribers in Cincinnati, OH | 132 |
| Spironolactone Other prescribers in Cincinnati, OH | 110 |
| Amlodipine Besylate Other prescribers in Cincinnati, OH | 92 |
| Furosemide Other prescribers in Cincinnati, OH | 89 |
| Carvedilol Other prescribers in Cincinnati, OH | 84 |
| Entresto (sacubitril/valsartan) Other prescribers in Cincinnati, OH | 83 |
| Atorvastatin Calcium Other prescribers in Cincinnati, OH | 83 |
| Jardiance (empagliflozin) Other prescribers in Cincinnati, OH | 82 |
| Warfarin Sodium Other prescribers in Cincinnati, OH | 78 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 44 payments worth $7,043 in total to this clinician.
| Bayer HealthCare Pharmaceuticals Inc. | $5,825 |
|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $310 |
| Abbott Laboratories | $304 |
| Zoll Respicardia, Inc. | $138 |
| Actelion Pharmaceuticals US, Inc. | $124 |
| Alnylam Pharmaceuticals Inc. | $116 |
| Daiichi Sankyo Inc. | $58.60 |
| Pfizer Inc. | $53.64 |
| Consulting Fee | $4,917 |
|---|---|
| Food and Beverage | $1,605 |
| Travel and Lodging | $521 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. May 17, 2025 | Consulting Fee Kerendia · Cardio-Renal | $4,917 |
| Bayer HealthCare Pharmaceuticals Inc. May 16, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Cleveland, OH · in-kind | $304 |
| Bayer HealthCare Pharmaceuticals Inc. May 17, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Cleveland, OH · in-kind | $174 |
| Bayer HealthCare Pharmaceuticals Inc. May 16, 2025 | Travel and Lodging Kerendia · Cardio-Renal · travel to Cleveland, OH · in-kind | $42.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,850 in research payments for these studies, mostly to the institutions running them.
- Dapagliflozin in Acute Decompensated Heart Failure
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.